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Abstract
Presynaptic voltage-gated calcium CaV2.2 channels play a privileged role in spinal level sensitization following
peripheral nerve injury. Direct and indirect inhibitors of CaV2.2 channel activity in spinal dorsal horn are analgesic in
chronic pain states. CaV2.2 channels represent a family of splice isoforms that are expressed in different combina-
tions according to cell-type. A pair of mutually exclusive exons in the CaV2.2 encoding Cacna1b gene, e37a and
e37b, differentially influence morphine analgesia. In mice that lack exon e37a, which is enriched in nociceptors, the
analgesic efficacy of intrathecal morphine against noxious thermal stimuli is reduced. Here we ask if sequences
unique to e37a influence: the development of abnormal thermal and mechanical sensitivity associated with periph-
eral nerve injury; and the actions of two other classes of analgesics that owe part or all of their efficacy to CaV2.2
channel inhibition. We find that: i) the analgesic efficacy of morphine, but not ziconotide or gabapentin, is reduced
in mice lacking e37a, ii) the induction and maintenance of behaviors associated with sensitization that accompany
peripheral nerve injury, do not require e37a-specific sequence, iii) intrathecal morphine, but not ziconotide or
gabapentin analgesia to thermal stimuli is significantly lower in wild-type mice after peripheral nerve injury, iv) the
analgesic efficacy of ziconotide and gabapentin to mechanical stimuli is reduced following nerve injury, and iv)
intrathecal morphine analgesia to thermal stimuli in mice lacking e37a is not further reduced by peripheral nerve
injury. Our findings show that the analgesic action of morphine, but not ziconotide or gabapentin, to thermal
stimuli is linked to which Cacna1b exon, e37a or e37b, is selected during alternative pre-mRNA splicing.
Keywords: Voltage-gated calcium channels, Neuropathic pain, Alternative splicing, Morphine, Ziconotide,
Gabapentin, Nociception, Analgesia, Spared nerve injury
Background
Neuropathic pain can develop following peripheral nerve
injury. Symptoms include persistent mechanical hyper-
sensitivity, thermal hypersensitivity, and spontaneous
pain [1]. Maladaptive changes in the expression and ac-
tivity of several ion channels in sensory neurons are im-
plicated in the development and maintenance of certain
chronic and neuropathic pain states [2].
CaV2.2 channels localize to synapses of primary nocicep-
tive neurons in the dorsal horn laminae I/II [3] and they
contribute to the control of neurotransmitter release from
sensory presynaptic terminals [4,5]. CaV2.2 knockout mice
are viable, but have impaired nociception [6-8] and re-
duced hyperalgesia and mechanical allodynia typically as-
sociated with nerve injury [8]. The activity of CaV2.2
channels may be up-regulated following peripheral nerve
injury, an event that could contribute to the sensory
hypersensitivity that characterizes neuropathic pain [9].
The therapeutic activities of three different classes of
analgesics depend fully or partly on their ability to in-
hibit CaV2.2 channels: Intrathecal ziconotide (ω-cono-
toxin MVIIA), a selective CaV2.2 blocker, is an effective
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analgesic in humans with otherwise intractable neuro-
pathic pain including pain from cancer and AIDS
[10,11]; opiate analgesics inhibit presynaptic CaV2.2
channels in the spinal dorsal horn via Gi/o protein
coupled μ-opioid receptors (MORs) [12-17] and gabapen-
tinoids act by binding to the calcium channel CaVα2δ-1
subunit to reduce CaV2 channel activity, in part, via effects
on protein trafficking [18-20] (Figure 1B).
CaV2.2 channel currents recorded in neurons represent
the collective activity of several CaV2.2 channel splice
isoforms with their own unique biophysical features [21].
Notably, the exon composition of CaV2.2 splice isoforms is
cell-specific and under the control of cell-specific splicing
factors [22]. Mutually exclusive exons, e37a and e37b, are
present in CaV2.2 mRNAs of nociceptors whereas, e37a-
containing CaV2.2 mRNAs are in low abundance else-
Figure 1 Cacna1b exon targeting strategy, and sites of action of three analgesics on CaV2.2 channels. A, Illustrates the mouse Cacna1b
gene on chromosome 2 between exons 34 and 41. Constitutive exons (gray bars), mutually exclusive exons (red and blue bars) and introns
(horizontal line) are shown. The region in Cacna1b targeted by homologous recombination is delineated by two arrows. The targeting construct
contains a second copy of e37b to replace wild-type e37a as previously reported [26]. The replacement e37b (dark blue) contains a silent muta-
tion that introduces a unique Xho I site to allow genotyping and tracking of the substituted exon. The possible mRNAs generated from wild-type
and e37b-only mice are shown. B, illustrates the sites of actions of gabapentin (CaVα2δ-1), ziconotide (CaV2.2 α1-subunit) and morphine (μ-opioid
receptor). Morphine action on CaV2.2-e37a and CaV2.2-e37b channels is different. CaV2.2-e37a channels are inhibited by both voltage-dependent,
Gβγ-dependent and voltage-independent, Gβγ-independent pathways, whereas CaV2.2-e37b channels are mostly sensitive to voltage-dependent,
Gβγ-dependent inhibition.
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where in the nervous system [23-25]. Levels of e37a-
CaV2.2 mRNAs are reduced in DRG 14 days after
peripheral nerve injury [24]. Injury-induced decrease in
e37a-CaV2.2 mRNA levels likely reduces e37a-specific
contributions to synaptic transmission.
Mutually exclusive e37a and e37b encode the proximal
32 amino acids in the C-terminus of CaV2.2 and during
pre-mRNA splicing either one or the other is selected
[23]. Nociceptors are more likely to express a combin-
ation of e37a-CaV2.2 and e37b-CaV2.2 mRNAs compared
to other neurons that express primarily e37b-CaV2.2
mRNAs [23,25]. E37a enhances the inhibitory actions of
opioids on CaV2.2 channels in cell lines and in neurons,
through a Gi/o protein-dependent, stimulus-independent
mechanism [26,27]. To assess the role of e37a in nocicep-
tion, we replaced e37a with e37b in the mouse Cacna1b
gene and showed that e37b-only mice behaved as wild-
type in response to noxious thermal stimuli, but intra-
thecal morphine was a less effective analgesia to thermal
stimuli in e37b-only mice compared to wild-type [26].
Here we analyze the role of e37a in: i) the development
and maintenance of thermal and mechanical hypersensi-
tivity that accompanies peripheral nerve injury, ii) the an-
algesic actions of ziconotide and gabapentin, and iii) the
analgesic actions of intrathecal morphine, ziconotide, and
gabapentin in mice post injury. We conclude that e37a of
Cacna1b has a specific role, not mimicked by e37b, in
spinal morphine analgesia, whereas e37a and e37b are
functionally interchangeable in mechanical and thermal
nociception.
Results
In this study, we test the role of e37a in comparison to
e37b, to behavioral responses evoked by thermal and
mechanical stimuli. We use mice in which we replaced
e37a in Cacna1b with a second copy of e37b - a ma-
nipulation that removes the contribution of e37a without
altering total CaV2.2 protein levels (Figure 1A) [26].
E37a-CaV2.2 channels are enriched in TRPV1-containing
nociceptors but e37b-only mice respond like wild-type
mice to thermal and mechanical stimuli [26]. Therefore,
we conclude that e37b substitutes functionally for e37a
in basal nociception (see Figure 2; 7 day time point prior
to injury).
Levels of e37a-CaV2.2 mRNA decrease in DRG follow-
ing peripheral nerve injury. We therefore tested if e37a
contributes to the development and maintenance of the
hypersensitivity that accompanies peripheral nerve in-
jury. Figure 2 shows that mice lacking e37a behave as
wild-type in the spared nerve injury (SNI) model of
chronic pain. Enhanced sensitivity to noxious thermal
and mechanical stimuli is not significantly different in
time course or magnitude between wild-type and e37b-
only mice. Behavioral responses were maximal in
ipsilateral but not contralateral hind paws one week fol-
lowing SNI surgery and were maintained over the 4-week
monitoring period. The expression and maintenance of
behaviors that accompany SNI in e37b-only mice pro-
gressed as in wild-type mice. We conclude that e37a-
CaV2.2 and e37b-CaV2.2 channels are equivalent in their
capacity to support enhanced thermal and mechanical re-
sponsiveness after SNI.
We also measured whole cell voltage-gated calcium
(CaV) channel currents in capsaicin-responsive, small
diameter neurons of dorsal root ganglia (DRG) L4, L5,
and L6 ipsilateral and contralateral to the injured nerve,
from WT and e37b-only mice. Endogenous CaV2.2 chan-
nel currents measure the overall expression levels of
functional CaV2.2 channels on the surface of sensory
neurons of wild-type and e37b-only mice. DRG neurons
express multiple classes of CaV channels and the most
reliable method to isolate pure CaV2.2 currents is by ω-
conotoxin GVIA (CgTx)-sensitivity. CaV currents were
recorded before (total CaV current) and after 2 μM CgTx
to selectively inhibit all CaV2.2 channels and, by toxin-
subtraction, CaV2.2 currents were separated from total
CaV current. I-V plots show the average CgTx-sensitive
(CaV2.2) and CgTx-insensitive (non-CaV2.2) calcium cur-
rents measured from contralateral and ipsilateral neurons
of wild-type and e37b-only mice. CaV current densities in
nociceptors are similar across all conditions (Figure 2C,
2D) demonstrating that CaV2.2 channels are expressed at
approximately equal levels in DRG of e37b-only and wild-
type mice [26]. Furthermore, the basic biophysical features
of CaV2.2 currents in nociceptors are not altered by SNI.
We showed previously (also see Figure 3A, 3C), that
e37a contributes significantly to the spinal level analgesic
actions of morphine [26] and that e37a-CaV2.2 mRNA
levels are reduced in ipsilateral but not contralateral
DRG, following peripheral nerve injury [24]. Here we
compare the maximum possible effect (MPE) of intra-
thecal morphine to lengthen paw withdrawal latencies in
response to thermal stimuli, contralateral and ipsilateral
to the injured nerve. The %MPE of morphine peaked
within 10–20 mins of injection in wild-type mice but
morphine efficacy against thermal stimuli applied ipsilat-
eral was substantially lower as compared to contralateral
testing (~ 30%, Figure 3A, 3B; P = 0.017, paired two-
tailed Student’s t-test) [28,29]. Reduced morphine effi-
cacy in peripheral nerve injury animal models may have
relevance to morphine tolerance in neuropathic pain
states in humans [30]. Interestingly, intrathecal morphine
analgesia was similar ipsilateral and contralateral to the in-
jured nerve against noxious thermal stimuli in e37b-only
mice (Figure 3A, 3C) (P = 0.777 ipsilateral compared to
contralateral, paired two-tailed Student’s t-test). We con-
clude that e37a confers properties, not found in e37b,
which contribute to the analgesic actions of morphine. In
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addition, the presence of e37a-CaV2.2 channels appear to
be necessary for the characteristic lowering of morphine
analgesia to noxious thermal stimuli that accompanies
peripheral nerve injury.
In contrast to its analgesic actions against noxious
thermal stimuli, intrathecal morphine was ineffective
against noxious mechanical stimuli in both wild-type
and e37b-only mice and regardless of nerve injury (data
not shown). The lack of intrathecal morphine analgesia
against mechanical stimuli is consistent with reports of
others [31-33] and with recent findings showing re-
stricted expression of MORs in TRPV1-containing DRG
neurons, which respond to noxious thermal stimuli, but
not in neurons that respond to noxious mechanical
stimuli [34].
Our findings suggest that amino acids encoded by
e37a, absent in e37b, are critical for the full inhibitory
action of MORs on CaV2.2 channels. We showed
previously that e37a enhances the inhibitory actions of
opioids on CaV2.2 channels in cell lines and in neurons,
through a Gi/o protein-dependent, stimulus-independent
mechanism [26,27]. However, our experiments do not
exclude the possibility that CaV2.2-e37b channels in
nociceptor afferents, as compared to CaV2.2-e37a, are
simply less sensitive to other drugs that act on CaV2.2
channels independent of G proteins.
Ziconotide (Conus magnus peptide ω-conotoxin MVIIA)
is a selective peptide inhibitor of CaV2.2 channels and it
occludes the central ion pore (Figure 1B) [35,36]. In
humans, ziconotide alleviates symptoms of intractable
chronic pain but unlike opiates, patients do not develop
tolerance during treatment [10,37].
We compared the inhibitory actions of ziconotide on
e37a-CaV2.2 and e37b-CaV2.2 channels transiently
expressed in tsA201 cells because its effects on these
isoforms have not been reported previously. Ziconotide
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Figure 2 Development of thermal and mechanical hypersensitivity after peripheral nerve injury in wild-type and e37b-only mice. A,
Paw withdrawal latency to noxious thermal stimuli applied to hindpaws ipsilateral (I) and contralateral (C) to the injury in wild-type (WT) and
e37b-only (e37b) mice (Hargreaves method). Latencies were measured at the time points indicated before and after injury (at time 0). P values
comparing latencies in WT and e37b-only mice were > 0.05 at all time points except at day 21 (P = 0.015). At days −8, -7, -1, 0, 3, 5, 7, 14, 21 and
28, P values were 0.37, 0.81, 0.07, 0.52, 0.85, 0.74, 0.90, 0.30, 0.71, and 0.87 contralateral; P values were 0.72, 0.81, 0.10, 0.87, 0.72, 0.28, 0.29, 0.83,
0.015 and 0.16 for ipsilateral. B, Paw withdrawal thresholds to mechanical stimuli applied to hindpaws in WT and e37b-only mice (von Frey fila-
ments). The 50% paw withdrawal threshold from the same side paw compared between WT and e37b-only mice: At days −8, -7, -1, 0, 3, 5, 7, 14,
21 and 28, P values were: 0.26, 0.44, 0.29, 0.63, 0.35, 0.28, 0.60, 0.21, 0.05 and 0.18 for contralateral; P values were 0.37, 0.72, 0.74, 0.65, 0.47, 0.24,
0.89, 0.67, 0.36 and 0.57 for ipsilateral. CaV2.2 currents measured from capsaicin-responsive neurons of dorsal root ganglia L4, L5 and L6. Total
calcium channel currents were recorded and current voltage-relationships generated in the absence and in the presence of ω-conotoxin GVIA
(D). CaV2.2 current was generated by toxin-subtraction (C). There is no consistent difference between CaV2.2 current and non-CaV2.2 currents
(CgTx-resistant) measured under the different conditions. Only cells responding to 1 μM capsaicin were analyzed. Values are average ± SE.
Student’s two-tailed t-test.
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(1 nM - 3 μM) inhibited e37a-CaV2.2 and e37b-CaV2.2
channel isoforms equally well; ~70% of channels were
inhibited at concentrations between 1 nM and 10 µM
(Figure 4). We did not test concentrations of ziconotide
below 1 nM using whole cell recording because of the
long incubation time required to achieve steady-state
inhibition.
We next compared the actions of intrathecal zicono-
tide (10 pmol, 27 ng) in wild-type and e37b-only mice.
Intrathecal ziconotide rapidly prolonged paw withdrawal
latencies to both thermal and mechanical stimuli. The
MPE of ziconotide peaked within 10 mins (Figure 5A,
5B) and declined slowly over the 3 hr monitoring period.
There were no significant differences in the analgesic ac-
tions of ziconotide against noxious thermal stimuli ap-
plied to hind paws, contralateral and ipsilateral to the
site of injury, between wild-type and e37b-only mice
(Figure 5C; P = 0.42 and P = 0.97). Similarly, ziconotide
was equally effective as an analgesic in behavioral re-
sponses to mechanical stimuli applied to hind paws,
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Figure 3 Percent maximum possible effect of intrathecal morphine after injury in wild-type and e37b-only mice. Latency to paw
withdrawal from thermal stimulus after intrathecal morphine injection (3 μg morphine sulfate) converted into percent maximum possible effect
(MPE) using formula: (PWLmorphine − PWLbaseline) × 100/(20 − PWLbaseline) for each time point indicated. A, Comparison of spinal morphine
effect in response to noxious thermal stimuli in WT mice measured from paws contralateral (WT-C) and ipsilateral (WT-I) to the site of injury. P
values at 0, 10, 20, 30, 40, 50 and 60 min after morphine injection were 0.32, 0.001, 1.5 × 10-5, 0.007, 0.4, 0.42 and 0.91. B, Area under the curve
(AUC) of the %MPE was calculated for each ipsilateral and contralateral paw and measurements from the same animals connected by a line.
There is a significant reduction in AUC for morphine analgesia in ipsilateral compared to contralateral measurements (P = 0.0174). C, Comparison
of spinal morphine effect in response to noxious thermal stimuli in e37b-only mice measured from paws contralateral (37b-C) and ipsilateral
(37b-I) to the site of injury. P values at 0, 10, 20, 30, 40, 50 and 60 min after morphine injection were 0.13, 0.76, 0.74, 0.44, 0.89, 0.66, 0.36. D, Area
under the curve of the %MPE was calculated for ipsilateral and contralateral measurements, connecting lines show measurements within each
animal. Average values and SE are shown (red symbols). There is no significant difference in AUC for morphine analgesia in ipsilateral compared
to contralateral measurements (P = 0.777). (Student’s two-tailed t-test for all comparisons).
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contralateral and ispilateral to the injured nerve, in wild-
type and e37b-only mice (Figure 5D; P = 0.59 and
P = 0.67). In contrast to intrathecal morphine, ziconotide
was effective against noxious mechanical stimuli, but
had reduced efficacy against stimuli applied ipsilateral to
the injured nerve similarly in wild-type (P = 0.016,
contralateral compared to ipsilateral) and e37b-only
mice and (P = 0.002, contralateral compared to ipsilat-
eral) (Figure 5D).
Finally, for completeness we tested the actions of
gabapentin in wild-type and e37b-only mice. Gabapentin
is an effective treatment in postherpetic neuralgia and
other types of neuropathic pain [38]. Although there is
little evidence for acute, direct inhibitory actions of
gabapentin and its analogue pregabalin on CaV2.2 chan-
nels [20,39], their analgesic activity depends on the
CaVα2δ-1 subunit that binds to, and modulates the traf-
ficking and activity of CaV2.2 channels [40]. We com-
pared the activity of intrathecal gabapentin (100 μg), as
previously described above, by measuring paw with-
drawal latencies to thermal stimuli and thresholds to
mechanical stimuli applied to hind paws ipsilateral and
contralateral to the injured nerve. The analgesic effects
of intrathecal gabapentin peaked within 10 mins follow-
ing injection and declined slowly over the 3 hr measure-
ment period.
The maximum possible effect of gabapentin to thermal
and mechanical stimuli applied contralateral and ipsilateral
to the injured nerve were not significantly different com-
paring between wild-type and e37b-only mice (Figure 6;
thermal: P = 0.17 and P = 0.47; mechanical: P = 0.12 and
P = 0.32). Injury did not significantly affect the analgesic
actions of gabapentin against noxious thermal stimuli
(WT: P = 0.54; e37b-only: P = 0.26) its actions were re-
duced against noxious mechanical stimuli in e37b-only
mice (P = 0.04). Nonetheless, gabapentin was still highly ef-
fective as an analgesic after injury (Figure 6D) when com-
pared to ziconotide (Figure 5D).
Discussion
CaV2.2 channels at afferent terminals in spinal dorsal
horn dominate in controlling glutamate and likely
substance P release from afferents in lamina I/II of the
spinal dorsal horn [5,13,41]. As importantly, CaV2.2
channel are essential for supporting the maladaptive
hypersensitivity that accompanies peripheral nerve in-
jury as evidenced by the effectiveness of CaV2.2 channel
inhibitors to alleviate behavioral symptoms associated
with chronic pain [10,37,42]. It is therefore essential to
define the precise class of CaV2.2 channels expressed in
nociceptors that are the therapeutic targets of MORs
and ziconotide. In this study we support the hypothesis
that e37a-CaV2.2 channels are targeted by spinal mor-
phine and that morphine analgesia depends on the
presence of e37a-CaV2.2 channels. When e37a-CaV2.2
channels are replaced with e37b-CaV2.2 channels, spinal
morphine is less effective against noxious thermal stim-
uli but importantly, the analgesic actions of ziconotide
that inhibits both isoforms equally well are unaffected
when e37a is replaced with e37b. However, nerve injury
did reduce the analgesic efficacy of ziconotide to mech-
anical stimuli. Ziconotide and gabapentin, owe all or
part of their analgesic efficacy to inhibition of CaV2.2
channels in dorsal horn [10,18,19]. Our findings suggest
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that cellular factors, that influence cell-specific splicing
of CaV2.2 pre-mRNAs, may in turn influence the spinal
level actions of morphine.
We do not know the identity of the splicing factors that
presumably regulate the selection of e37a over e37b or
vice versa, during alternative splicing of CaV2.2 pre-
mRNA. However, we have shown previously that levels of
e37a-CaV2.2 mRNAs decrease selectively in injured but
not in uninjured dorsal root ganglia of wild-type mice
[24]. Interestingly, the reduction in spinal morphine anal-
gesia to noxious thermal stimuli that accompanies periph-
eral nerve injury (Figure 3) - precisely when maximal
therapeutic efficacy is desirable - is similar in overall
magnitude to the reduced spinal morphine analgesia in
e37b-only mice compared to wild-type (Figure 3). More-
over, in mice lacking e37a, nerve injury does not further
reduce morphine analgesia, an observation that raises the
possibility that nerve injury and loss of e37a share a com-
mon pathway with respect to morphine action.
In superficial lamina of spinal dorsal horn, MORs
inhibit presynaptic CaV2.2 channels as well as activate
postsynaptic G protein coupled inwardly rectifying
potassium GIRK2 channels [43]. However, presynaptic
CaV2.2 channels appear to be the main targets of MOR in-
hibition of monosynaptic Aδ- and C-fiber-evoked excita-
tory postsynaptic currents in lamina I neurons and are
thus positioned at the critical first junction of the pain
transduction pathway [13].
Intrathecal morphine analgesia to noxious thermal
stimuli is influenced by the expression of the e37a splice
isoform of CaV2.2, whereas ziconotide and gabapentin
analgesia are not. We also find that the analgesic effica-
cies of gabapentin and most strikingly of ziconotide to
mechanical stimuli are reduced following nerve injury
(Figures 5D, 6D). Our findings raise the possibility that
presynaptic channels other than CaV2.2 may dominate in
the transmission of noxious mechanical stimuli after
nerve injury. Ziconotide and gabapentin are used clinic-
ally as analgesics to relieve the symptoms of neuropathic
pain [37,44-47] but neither act on CaV2.2 channels via
GPCRs or are influenced by e37a [11,39,48,49]. Thus
functionally, e37b substitutes for e37a in many cellular
activities involving CaV2.2 channels, but not fully in
Gi/oPCR signaling to the channel.
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Figure 5 Analgesic actions of intrathecal ziconotide against noxious thermal and mechanical stimuli in nerve injury model. A, Latency
to paw withdrawal from thermal stimulus after intrathecal ziconotide injection (10 pmol) represented as percent maximum possible effect (MPE)
for each time point indicated. A, B, Comparison of spinal ziconotide analgesia in response to noxious thermal stimuli in WT (A) and e37b-only
(B) mice measured from paws contralateral (C) and ipsilateral (I) to the site of injury. P values at all time points were > 0.05. C, D, Area under the
curve of %MPE calculated for each ipsilateral and contralateral paw in response to noxious thermal (C) and mechanical (D) stimuli for WT and
e37b mice plotted individually for each animal and connected by a line. Averages are also shown (red). There is a significant decrease in zicono-
tide efficacy after injury in WT and e37b-only mice (P = 0.017 and 0.002, respectively) whereas there was no difference between genotypes (WT
compared to e37b-only P = 0.59 for contralateral and 0.69 for ipsilateral measurements). Student’s two-tailed t-test for all comparisons.
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Morphine analgesia to thermal stimuli is influenced
by e37a and e37b cannot fully substitute for e37a in
mediating its actions on CaV2.2 channels. This is con-
sistent with what we know about the mechanism of
Gi/oPCR inhibition of CaV2.2 channels including by
MORs. Whereas all CaV2.2 channel isoforms we have
studied to date are inhibited by Gi/oPCRs via a Gβγ-
dependent mechanism that is voltage-dependent, CaV2.2
channels containing e37a are additionally susceptible to
inhibition by a mechanism that is Gβγ-independent and
voltage-independent (Figure 1B; [26,27]). Similar to our
findings, spinal level morphine would therefore be most
effective under conditions that favored the presence of
e37a-CaV2.2 at afferent terminals and during periods of
high neuronal activity (Figure 1A) [26,27].
Although in this study we have focused on CaV2.2
splice isoforms as modulators of the anti-nociceptive ac-
tions of morphine, other receptors and ion channels,
most notably MORs, are also critical. For example, MOR
levels are significantly reduced in DRG neurons following
nerve injury [50]. Thus, the direction of changes in both
MOR and its target CaV2.2-e37a channel in DRG follow-
ing injury combine to reduce morphine action in spinal
dorsal horn. By contrast, ziconotide analgesia against
noxious thermal stimuli is independent of nerve injury,
CaV2.2 channel splice isoform, and MOR expression
levels. In the clinic, ziconotide use is limited by side effects
that include psychoses, and these are not generally toler-
ated except by the most severely ill patients [10,11,37,42].
Thus, small molecule inhibitors of presynaptic CaV2.2
channels with preferential action in the spinal dorsal horn
could be therapeutically valuable. In this regard, drugs de-
signed to preferentially target and inhibit e37a-specific se-
quences or e37a-specific CaV2.2 channel activity could be
analgesic and have reduced side effects (because of re-
duced action on other CaV2.2 splice isoforms). Even
though e37a-CaV2.2 mRNA levels fall in DRG following
nerve injury, acute knockdown of e37a-CaV2.2 mRNAs by
siRNA reverses thermal hypersensitivity that accompanies
nerve injury [24]. Thus it is possible that e37a-CaV2.2
channels are preferentially expressed at nociceptor termi-
nals in spinal dorsal horn and as such represent a valuable
therapeutic target to alleviate neuropathic pain [24,26].
Substantial evidence points to extensive alternative
splicing of multi-exon mammalian genes according to
cell-type, developmental stage, disease, and injury [21].
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Figure 6 Analgesic actions of intrathecal gabapentin against noxious thermal and mechanical stimuli. Latency to paw withdrawal from
thermal stimulus after intrathecal gabapentin injection (100 μg) represented as percent maximum possible effect (MPE) for each time point
indicated. A, B, Comparison of spinal gabapentin analgesia in response to noxious thermal stimuli in WT (A) and e37b-only (B) mice measured
from paws contralateral (C) and ipsilateral (I) to the site of injury. P values at all time points were > 0.05. C, D, Area under the curve of %MPE calcu-
lated for each ipsilateral and contralateral paw in response to noxious thermal (C) and mechanical (D) stimuli for WT and e37b mice plotted indi-
vidually for each animal and connected by a line. Averages are also shown (red). Gabapentin analgesia against noxious mechanical stimuli was
slightly but not significantly less effective ipsilateral compared to contralateral to the injured nerve in WT mice (P = 0.11) and less effective ipsilat-
eral compared to contralateral to the injured nerve in e37b-only mice (P = 0.04). Student’s two-tailed t-test.
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It can be technically challenging to determine the cellu-
lar and behavioral consequences of individual alternative
splicing events when isoform-specific drugs and anti-
bodies are lacking. Nonetheless, our exon-replacement
strategy demonstrates the functional significance of an
individual alternatively spliced exon in the Cacna1b gene
in the context of thermal nociception. The more pre-
cisely we can define cell-specific isoforms of major ion
channel and receptor drug targets, within their appropri-
ate cellular and disease contexts, the more precisely we
can inform therapeutic strategies.
Methods
Animals
Animal housing and experimental procedures were car-
ried in accordance with the Brown Institutional Animal
Care and Use Committee guidelines. 2–3 month old
male mice of mixed genetic background were used (pre-
dominantly 129 and C57BL6). Wild-type mice were bred
in parallel with e37b-only mice to obtain matched genetic
backgrounds [26]. The e37b-only mouse line contains a
second copy of e37b, replacing e37a, in the Cacna1b gene
[26]. Nociceptors of dorsal root ganglia from wild-type
mice express both e37a and e37b isoforms [23].
Surgery
Spared nerve injury model (SNI) was performed accord-
ing to methods described in [51]. Briefly, after exposing
the three branches of the sciatic nerve (common peroneal,
tibial and sural) in anesthetized mice, the common
peroneal and tibial branches were carefully segregated from
surrounding tissues, tightly ligated and axotomized ~2 mm
of the distal nerve stump. The sural branch was left intact.
Behavioral analyses were performed on days 7 and 1 before
surgery, on the day of surgery (0) and then 1, 3, 5, 7, 14, 21
and 28 days after surgery.
Behavioral analyses
We measured sensitivity of the hindpaw to thermal and
mechanical stimuli in wild-type and e37b-only mice
contralateral and ipsilateral to the injury. To assess ther-
mal sensitivity, we measured paw withdrawal latencies
using Plantar Testing Instruments (IITC) [52]. A high-
intensity beam (setting = 20%, ~45 W) was applied to the
middle of the plantar surface of a resting mouse. Paw-
withdrawal latency (PWL) was measured to the nearest
0.1 s with a cut-off value of 20 s. To assess mechanical
sensitivities we measured thresholds for paw withdrawal,
using up and down method, in response to a graded series
of von Frey filaments (0.008, 0.02, 0.04, 0.07, 0.16, 0.4, 1,
2 g) applied to the glabrous surface of the hind paw. The
maximum mechanical stimulus applied was 2 g [53]. To
determine analgesia efficacies, we injected 3 μg morphine
sulfate, 10 pmol ziconotide or 100 μg gabapentin
intrathecally using a 28 gauge needle connected to a micro
syringe through a 15 PE 50 polyester catheter (15 cm).
Mice were anesthetized with 2% isofluorane during the
entire surgery [44]. We monitored the analgesic effects of
each drug measuring paw withdrawal latencies to a ther-
mal stimulus and paw withdraw thresholds to mechanical
stimuli before and at 10 min intervals following drug in-
jection, testing continued for 60 mins for morphine and
3 hrs for ziconotide and gabapentin. Analgesia efficacy
was calculated as % maximum possible effect for wild-
type and e37a-lacking mice: %MPE = (PWLdrug − PWLbase-
line) *100/(20 − PWLbaseline). The area under the curve of
% MPE (AUC) was used to compare overall drug effica-
cies. Each measurement reflects average data from at least
10 different animals for each condition.
Electrophysiology on acutely dissociated dorsal root
ganglia neurons
Whole cell patch clamp recordings were obtained from
individual neurons acutely dissociated from DRG L4, L5
and L6 ipsilateral and contralateral to the site of injury.
DRG were isolated 14–28 days after surgery and behav-
ioral testing was performed to confirm the presence of
hypersensitivity to thermal and mechanical stimuli.
Voltage-gated calcium currents were recorded as de-
scribed previously using 1 mM calcium as the charge
carrier [26]. All neurons were challenged with 1 μM
capsaicin and only capsaicin-responsive neurons were
included in Figure 2. The fraction of capsaicin-responsive
and non-responsive neurons was the same independent of
injury and genotype.
Ziconotide inhibition of CaV2.2 splice isoforms tested in
tsA201 cells
We used tsA201 cells to transiently express CaV2.2 e37a
and e37b splice isoforms Genbank AF055477 &
AF055477. All Lipscombe clones used in our study are
deposited with Addgene. Cells were transfected using
lipofectamine 2000 (Invitrogen) with one of either e37a-
CaV2.2 or e37b-CaV2.2 cDNA together with CaVβ3
(Lipscombe/Addgene plasmid 26574) CaVα2δ-1 (Lips-
combe/Addgene Plasmid 26575) and eGFP (Clontech).
After 24 hours of expression, we performed standard
whole cell patch clamp recordings as described in [27].
Extracellular solution (mM): 1 CaCl2, 4 MgCl2, 10
HEPES, 135 tetraethyl ammonium chloride (TEA-Cl),
pH 7.2 with TEAOH. Internal solution (mM): 126 CsCl,
10 EGTA, 1 EDTA, 10 HEPES, 4 MgATP, pH 7.2 with
CsOH. Ziconotide was perfused onto the cell using fine
glass pipettes placed in close proximity as used in [26].
Statistical analysis
In all experiments including behavioral analyses and
electrophysiology analyses the experimenter collecting
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data was blinded to genotype and clone. The genotype
and clone identities were revealed only after all data were
collected and analyzed. Data presented are mean ± SE.
Comparison of mean differences between wild-type and
e37b-only mice were made by unpaired two-tailed Stu-
dent’s t-test. Comparison of mean differences between
contralateral and ipsilateral threshold values within indi-
vidual genotypes were made by paired two-tailed Student’s
t-test. Where relevant, P values are shown in text.
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